Abstract
Background Culex pipiens is the vector of a large number of pathogenic pathogens in humans. Using insecticides to deal with this vector is the most important way to control it. However, in recent decades, resistance to insecticides has been reported in this vector. One of the main insecticides used to fight this vector is organochlorine insecticides. Based on this, this study was conducted to investigate the prevalence of Knockdown resistance (kdr) in Culex pipiens against organochlorine insecticides.
Methods This study was conducted by systematic review and meta-analysis in the field of kdr prevalence in Culex pipiens against organochlorine insecticides. Based on this, during the search in the scientific databases PubMed, Web of Science, biooan.org, Embase, ProQuest, Scopus, and Google Scholar without time limit until the end of November 2023, all related articles were extracted and analyzed. The statistical analysis of the data was performed using the random and fixed effects model in the meta-analysis, Cochran’s test, I2 index, and meta-regression by STATA software version 17.
Results seven studies with a sample size of 2,029 Culex pipiens were included in the meta-analysis process. Based on the findings, the kdr resistance prevalence against Deltamethrin, Malathion, Permethrin, and DDT insecticides was estimated as 30.6%, 42%, 17.9%, and 76.3% respectively. Among them, the highest resistance to DDT and the lowest to Permethrin was observed.
Conclusion Based on the findings, a large proportion of Culex pipiens mosquitoes were resistant to DDT insecticide. However, this vector was highly sensitive to Deltamethrin, Malathion, and Permethrin insecticides. Due to the different resistance ratios in different regions of the world, it is recommended to conduct studies on the prevalence of kdr in Culex pipiens.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript